Please login to the form below
Sangamo
This page shows the latest Sangamo news and features for those working in and with pharma, biotech and healthcare.
Biogen bulks up in Alzheimer’s again with $2.7bn Sangamo deal
Sangamo’s zinc finger protein transcription factor (ZFP-TF) approach involves introducing double-stranded DNA breaks engineered to target specific sequences in a cell. ... Sangamo also has a gene therapy platform, with a first candidate for haemophilia
Latest news
-
Presidential hopeful Bernie Sanders criticises BioMarin’s gene therapy price
This includes Sangamo and Pfizer, whose gene therapy achieved a dose-dependent increase in clotting Factor VIII levels across four dosage groups, each including two subjects.
-
UK’s CMA clears Roche’s $4.3bn takeover of Spark
Athough, analysts at Jefferies have previously suggested that with a number of other companies developing gene therapies – including BioMarin, Sangamo and UniQure – that should not be considered overly dominant.
-
Sangamo steps up BioMarin chase with haemophilia gene therapy data
Updated results presented at ASH 2019. Sangamo has been playing catch-up with BioMarin in the race to develop a gene therapy for haemophilia A, but new data reported at the ... Sangamo is adamant that it is still in contention in the haemophilia A gene
-
Roche moving closer to approval of Spark takeover; report
number of other companies developing gene therapies – including BioMarin, Sangamo and UniQure – that should not be considered overly dominant.
-
Pfizer goes big on gene therapy with $500m facility spend
That was followed swiftly by a partnership with Spark Therapeutics that brought in a clinical-stage haemophilia B therapy now in phase 3 testing, and another deal with Sangamo for a
More from news
Approximately 10 fully matching, plus 20 partially matching documents found.
Latest Intelligence
-
Alzheimer’s: the search for a cure
gene-editing specialist Sangamo for rights to tau-targeting drug ST-501 as part of a broader R&D alliance.
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
The success or failure of Bluebird will be closely watched by a slew of cell and gene therapy companies including Sangamo, BioMarin (with exciting potential cures for haemophilia) and UniQure, looking
-
2019: CRISPR and therapeutic gene editing comes of age
Editas, and the failure of Sangamo Therapeutics’ rival zinc-finger nucleases (ZFNs) platform. ... Editas, CRISPR, Sangamo, Cellectis/Allogene and their peers to take the slow road to proving that gene- editing can deliver safe and effective
-
The handover: Pfizer reshapes itself for a new era
It has gene therapy deals with Spark in haemophilia and with Sangamo in ALS.
-
Deal Watch table for January 2014
320. Sangamo/Biogen Idec . Collaboration and licence. Development of therapies for haemoglobinopathies using zinc finger genome editing.
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest appointments
-
Eric Rhodes becomes CEO of ERS Genomics
Prior to joining Horizon Discovery, Rhodes held a number of senior positions including director of business development at Sigma-Aldrich and vice president of business development and alliance management at Sangamo
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- FDA approves Roche’s Actemra COVID-19 trial
- Roche’s Ocrevus boasts positive long-term data in MS
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- Low-dose LSD looks safe for Alzheimer’s patients, but will it work?
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Envision Pharma Group scoops two Silvers at the PM Society Digital Awards 2020
- Alone we can do so little, together we can do so much
- What can't we afford to treat anymore?
- OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
PMHub
Empowering Strategic Performance Ltd
OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
